IMpact of the AT2 receptor agonist c21 on blood pressure and beyond

Current Hypertension Reports

Volumn 14, Issue 5, 2012, Pages 403-409

  Foulquier, Sébastien ^a   Steckelings, U Muscha ^b   Unger, Thomas ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin; Antihypertensive drug therapy; AT2R; Blood pressure; C21; Compound 21; Hypertension; Inflammation; RAS; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; CANDESARTAN; COMPOUND 21; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; OLMESARTAN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BINDING AFFINITY; BLOOD PRESSURE REGULATION; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; HYPERTENSION; INHIBITION KINETICS; NATRIURESIS; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION; VASCULAR DISEASE; VASODILATATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; SULFONAMIDES; THIOPHENES; VASODILATOR AGENTS;

EID: 84870523200     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0291-6     Document Type: Review

References (44)

1. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;165:196-203.
2. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens. 1999;17:1775-86.
3. Vincent J-M, Kwan YW, Chan SL, et al. Constrictor and dilator effects of angiotensin II on cerebral arterioles. Stroke. 2005;36:2691-5.
4. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-7.
5. Meffert S, Stoll M, Steckelings UM, et al. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol. 1996;122:59-67.
6. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides. 2005;26:1401-9.
7. Wu L, Iwai M, Li Z, et al. Regulation of inhibitory protein-κB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells.Mol Endocrinol. 2004;18:666-78.
8. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab. 2000;11:1-6.
9. Wruck CJ, Funke-Kaiser H, Pufe T, et al. Regulation of transport of the angiotensin AT2 receptor by a novel membraneassociated Golgi protein. Arterioscler Thromb Vasc Biol. 2005;25:57-64.
10. Rodrigues-Ferreira S, Nahmias C: An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol Metab. 2010, 21: 684-690. This article reviews recent discoveriesconcerning a family of AT2 receptor-interacting proteins involved in the AT2R signaling, regulation and function.
11. Stoll M, Hahn AWA, Jonas U, et al. Identification of a zinc finger homoeodomain enhancer protein after AT(2) receptor stimulation by differential mRNA display. Arterioscler Thromb Vasc Biol. 2002;22:231-7.
12. Senbonmatsu T, Saito T, Landon EJ, et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 2003;22:6471-82.
13. Funke-Kaiser H, Reinemund J, Steckelings UM, Unger T: Adapter proteins and promoter regulation of the angiotensin AT2 receptor-implications for cardiac pathophysiology. J Renin Angiotensin Aldosterone Syst 2010, 11: 7-17. This article reviews new identified pathways implied in the modulation of signaling, expression and function of AT2R, especially via AT2R adapter proteins and heterodimer formation.
14. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31:349-55.
15. Pees C, Unger T, Gohlke P. Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats. Int J Biochem Cell Biol. 2003;35:963-72.
16. Touyz RM, Endemann D, He G, et al. Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension. 1999;33:366-72.
17. Widdop RE, Vinh A, Henrion D, Jones ES. Vascular angiotensin AT2 receptors in hypertension and ageing. Clin Exp Pharmacol Physiol. 2008;35:386-90.
18. Foulquier S, Dupuis F, Perrin-Sarrado C, et al. High salt intake abolishes AT2-mediated vasodilation of pial arterioles in rats. J Hypertens. 2011;29:1392-9.
19. Li J, Culman J, Hörtnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005;19:617-9.
20. Makino I, Shibata K, Ohgami Y, et al. Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides. 1996;30:596-601.
21. Steckelings UM, Paulis L, Unger T, Bader M. Emerging drugs which target the renin-angiotensin-aldosterone system. Expert Opin Emerg Drugs. 2011;16:619-30.
22. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008.
23. Bosnyak S, Welungoda IK, Hallberg A, et al.: Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br. J. Pharmacol. 2010, 159: 709-716. This is the first study demonstrating a C21-induced vasorelaxation in vitro that is translated into a vasodepressor response in vivo when combined with a low dose of AT1R blocker.
24. Hilliard LM, Jones ES, Steckelings UM, et al. Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension. 2012;59:409-14.
25. Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32:248-55.
26. Matavelli LC, Huang J, Siragy HM: Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 2011, 57: 308-313. This study provides evidence for the anti-inflammatory actions of C21 in clipped kidney of the Goldblatt hypertension model.
27. Rehman A, Leibowitz A, Yamamoto N, et al.: Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension 2012, 59: 291-299. This is the first study reporting effects of chronic C21 treatment on the vascular wall in genetic hypertensive rats. C21 reduced the stiffness of mesenteric resistance arteries independently of any blood pressure reduction.
28. Paulis L, Becker STR, Lucht K, et al.: Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 2012, 59: 485-492. This is the first study reporting the effects of chronic C21 treatment on the vascular wall in a hypertension-induced model. C21 prevented aortic stiffening independently of any blood pressure reduction.
29. Gelosa P, Pignieri A, Fändriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-51.
30. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142:821-30.
31. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112-6.
32. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptorblocked rats. Hypertension. 2001;38:1272-7.
33. Kaschina E, Grzesiak A, Li J, et al.: Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008, 118: 2523-2532. This is the first in vivo study using C21. A short treatment with C21 improved cardiac function and decreased scar size after myocardial infarction. This was observed in association with a decrease in inflammation and apoptosis markers.
34. Jehle AB, Xu Y, Dimaria JM, et al. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J Cardiovasc Pharmacol. 2012;59:363-8.
35. Rompe F, Artuc M, Hallberg A, et al.: Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010, 55: 924-931. This is the first study showing anti-inflammatory effects of direct AT2R stimulation by C21 in vitro and in vivo. Underlying signaling mechanisms are reported.
36. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285:1276-9.
37. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-8.
38. Sánchez PL, Villa A, Sanz R, et al. Present and future of stem cells for cardiovascular therapy. Ann Med. 2007;39:412-27.
39. Durik M, Sevá Pessôa B, Roks AJM: The renin-angiotensin system, bone marrow and progenitor cells. Clin. Sci. 2012, 123: 205-223. This review addresses the impact of renin-angiotensinsystem modulation on tissue regeneration by progenitor cells. In particular, they highlight the potential importance of AT2R stimulation with agonists in the future of stem cell therapy.
40. Numasawa Y, Kimura T, Miyoshi S, et al. Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. Stem Cells. 2011;29:1405-14.
41. Iwanami J, Mogi M, Li J-M, et al. Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice. Stroke. 2008;39:2554-9.
42. Curato C, Slavic S, Dong J, et al.: Identification of noncytotoxic and IL-10-producing CD8 + AT2R + T cell population in responseto ischemic heart injury. J. Immunol. 2010, 185: 6286-6293. This study revealed the expression of AT2R in CD8+ T cells in the periinfarct myocardium, thus revealing an AT2R-mediated cellular mechanism in regulating immune response during ischemic heart injury.
43. Altarche-Xifró W, Curato C, Kaschina E, et al. Cardiac c-kit + AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance. Stem Cells. 2009;27:2488-97.
44. Lauer D, Slavic S, Sommerfeld M, et al. AT2 receptor stimulation improves cardiac function 6 weeks after myocardial infarction in the rat. [Abstract ESH 8 C.03] Presented at the 22nd European Meeting on Hypertension and Cardiovascular Prevention. London, Great Britain, April 26-29, 2012.